

## WEST Search History

DATE: Friday, May 07, 2004

<b>Hide?</b>	<b>Set Name</b>	<b>Query</b>	<b>Hit Count</b>
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L10	L8 with treat\$4	135
<input type="checkbox"/>	L9	L8 same treat\$4	253
<input type="checkbox"/>	L8	interleukin with leukemia	1186
<input type="checkbox"/>	L7	interleukin same leukemia	2212
<input type="checkbox"/>	L6	L5 and ceramide	8
<input type="checkbox"/>	L5	L4 and interleukin	90
<input type="checkbox"/>	L4	L3 and leukemia	386
<input type="checkbox"/>	L3	L2 and (tumor or cancer or leukemia)	1378
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L2	(544/1,224,242;536/1.11,4.1;514/23,25,27 ) [CCLS]	4789
<input type="checkbox"/>	L1	(544/1,224,242;536/1.11,4.1;514/23,25,27 )! [CCLS]	4789

END OF SEARCH HISTORY

## WEST Search History

DATE: Friday, May 07, 2004

<b>Hide?</b>	<b><u>Set Name</u></b>	<b><u>Query</u></b>	<b><u>Hit Count</u></b>
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L6	L5 and ceramide	8
<input type="checkbox"/>	L5	L4 and interleukin	90
<input type="checkbox"/>	L4	L3 and leukemia	386
<input type="checkbox"/>	L3	L2 and (tumor or cancer or leukemia)	1378
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L2	(544/1,224,242;536/1.11,4.1;514/23,25,27 ) [CCLS]	4789
<input type="checkbox"/>	L1	(544/1,224,242;536/1.11,4.1;514/23,25,27 )! [CCLS]	4789

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 12:39:29 ON 07 MAY 2004)

FILE 'CAPLUS, MEDLINE, USPATFULL, EUROPATFULL' ENTERED AT 12:39:47 ON 07  
MAY 2004

L1	279725	S	INTERLEUKIN
L2	87350	S	INTERLEUKIN-2
L3	34428	S	L2 AND (TUMOR OR CANCER)
L4	7681	S	L3 AND LEUKEMIA
L5	0	S	L4 AND CCRF/CEM
L6	310	S	L4 AND "CCRF/CEM"
L7	5	S	L6 AND CERAMIDE

L7 ANSWER 1 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2004:31093 USPATFULL  
TITLE: System for identifying and analyzing expression of  
are-containing genes  
INVENTOR(S): Abu-Khabar, Khalid S., Riyadh, SAUDI ARABIA  
Williams, Bryan R.G., Cleveland, OH, UNITED STATES  
Frevel, Mathias, Wellington, NEW ZEALAND  
Silverman, Robert H., Beachwood, OH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023231	A1	20040205
APPLICATION INFO.:	US 2003-257294	A1	20030714 (10)
	WO 2001-US11993		20010412
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Pamela A Docherty, Calfee Halter & Griswold, 1400 Mc Donald Investment Center, 800 Superior Ave, Cleveland, OH, 44114		
NUMBER OF CLAIMS:	83		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Page(s)		
LINE COUNT:	3591		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a gene discovery system and gene expression systems specific for genes encoding ARE-containing mRNAs. In one aspect, the present invention relates to computational methods of selecting coding sequences of ARE-genes from databases using a one or more ARE search sequences. The ARE search sequences are from 10 to 80 nucleotides in length and comprise a sequence which is encompassed by one of the following two sequences: (a) WU/T(AU/TU/TU/TA)TWWW, SEQ ID NO. 1, wherein none or one of the nucleotides outside of the parenthesis is replaced by a different nucleotide, and wherein W represents A, U, or T; and (b) U/T(AU/TU/T/U/T)n, SEQ ID NO. 2, wherein n indicates that the search sequence comprises from 3 to 12 of the tetrameric sequences contained within the parenthesis. The method comprises extracting from the databases, those nucleic acids whose protein coding sequences are upstream and contiguous with a 3' untranslated region (UTR) that comprises one of the ARE search sequences. The present invention also relates to methods of selectively amplifying RNA and cDNA molecules using primers derived from and complementary to the consensus 5' sequence motifs and primers derived from and complementary to the ARE search sequence. The present invention also relates to methods of selectively amplifying ARE genes which employ a 3' primer which is from 15 to 50 nucleotides and length and comprises from 2 to 10 pentamers having the sequence TAAAT. The pentameric sequences in the primers are either overlapping or non-overlapping. The 3' primers are used in the reverse transcription step of the methods, the polymerase chain reaction (PCR) amplification step of the methods, or in both the reverse transcription step and the PCR amplification step of the methods. The present invention also relates to methods of making libraries which comprise portions of the ARE genes that are selectively amplified by the present methods and to methods of making microarrays which comprise probes that hybridize under stringent conditions to portions of the protein coding sequences of the ARE genes that are selectively amplified by the present methods. The present invention also relates to libraries and the microarrays that are made by such methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2003:265322 USPATFULL  
TITLE: Novel death associated proteins, and THAP1 and PAR4

pathways in apoptosis control  
INVENTOR(S): Girard, Jean-Philippe, Rebigue, FRANCE  
Amalric, Francois, Toulouse, FRANCE  
Roussigne, Myriam, La Bastide sur L'Hers, FRANCE  
Kossida, Sophia, Basel, SWITZERLAND  
Clouaire, Thomas, Toulouse, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186337	A1	20031002
APPLICATION INFO.:	US 2002-317832	A1	20021210 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341997P	20011218 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614	
NUMBER OF CLAIMS:	80	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	13503	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to genes and proteins of the THAP (THanatos (death)-Associated Protein) family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to the Par4 protein and SLC chemokine pathways, including the interaction of Par4 and SLC with THAP family proteins, and the recruitment and localization of Par4 to PML nuclear bodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 5 USPATFULL on STN  
ACCESSION NUMBER: 2003:71949 USPATFULL  
TITLE: Compounds that enhance tumor death  
INVENTOR(S): Dawson, Glyn, Chicago, IL, UNITED STATES  
Cho, Seongeun Julia, Hillsborough, NJ, UNITED STATES  
PATENT ASSIGNEE(S): The University of Chicago (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003050236	A1	20030313
APPLICATION INFO.:	US 2001-930559	A1	20010815 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225526P	20000815 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gina N. Shishima, FULBRIGHT & JAWORSKI L.L.P., SUITE 2400, 600 CONGRESS AVENUE, AUSTIN, TX, 78701	
NUMBER OF CLAIMS:	57	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	6478	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns compositions that modulate palmitoyl protein thioesterase 1 (PPT1) activity, as well as methods for using these compositions as a therapeutic treatment to inhibit a cancer cell, such as by promoting apoptosis of the cancer cell. It is contemplated that these compositions may be used in conjunction with other anti-cancer therapies such as

chemotherapeutic agents. PPT1 modulators include polypeptide and peptides that competitively interact with PPT1, as well as PPT1 antisense and ribozyme constructs that prevent the expression of PPT1. Furthermore, the present invention also covers methods of screening for PPT1 modulators, as well as for levels of PPT1 amount or activity as a diagnostic tool.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2001:182699 USPATFULL  
TITLE: High level cytokine production with enhanced cell viability  
INVENTOR(S): Lau, Allan S., Fremont, CA, United States  
Ossina, Natalya, Albany, CA, United States  
Hoyt, Kenneth, San Rafael, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001031859	A1	20011018
APPLICATION INFO.:	US 2001-772109	A1	20010126 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-657881, filed on 8 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-152854P	19990908 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	IOTA PI LAW GROUP, 350 CAMBRIDGE AVENUE SUITE 250, P O BOX 60850, PALO ALTO, CA, 94306-0850	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2180	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions and methods for enhanced cytokine production in human cell culture, particularly under conditions where apoptotic cell death is suppressed by expression of CrmA.

CAS INDEXING IS AVAILABLE FOR THIS PATENT..

L7 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2001:55742 USPATFULL  
TITLE: Adjuvant incorporation into antigen carrying cells: compositions and methods  
INVENTOR(S): Ravindranath, Mepur H., Los Angeles, CA, United States  
Morton, Donald L., Malibu, CA, United States  
PATENT ASSIGNEE(S): John Wayne Cancer Institute, Santa Monica, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6218166	B1	20010417
APPLICATION INFO.:	US 1995-462106		19950605 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-353549, filed on 9 Dec 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Minnifield, Nita		
LEGAL REPRESENTATIVE:	Fulbright & Jaworski LLP		
NUMBER OF CLAIMS:	103		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 23 Drawing Page(s)		

LINE COUNT:

5039

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are compositions and methods for enhancing the antibody and T cell response to cellular antigens by incorporating an immunopotentiating agent into the cellular membrane or into an intracellular compartment. Such adjuvant-incorporated cell compositions are useful in methods to increase immune responses against antigens, including immunologically cryptic **tumor** cell antigens, and may be employed to generate useful diagnostic antibodies, to elicit anti-**tumor** effects in immunized animals, and to significantly prolong survival in animals with **cancer**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>